Abstract Details

Title Profile of serum biomarkers in seronegative NMOSD

Topic Autoimmune Neurology

Presentation(s) S50 - Autoimmune Neurology: NMOSD (5:06 PM-5:18 PM)

Poster/Presentation
Number 009

Objective Aim of this study is to characterise the neuronal, axonal, and glial damage in seronegative NMOSD in comparison with AQP4+NMOSD

Background serum GFAP and NfL define disease activity in different neurological conditions. These biomarkers increase in patients with AQP4+NMOSD during clinical attacks, with contradictory results in seronegative-NMOSD.

Design/Methods patients with double (i.e. for AQP4 and MOG-Abs) seronegative-NMOSD and age-matched AQP4+NMOSD with available onset/relapse serum samples (i.e. obtained within 3 months) were retrospectively enrolled. Clinical and radiological data were collected. Serum NfL, GFAP, Tau and UCH-L1 levels were determined using an ultrasensitive paramagnetic bead-based enzyme-linked immunosorbent assay (SIMOA). Statistical analysis was performed using parametric and non-parametric tests and ROC analysis

Results

27 seronegative-NMOSD and 24 AQP4+NMOSD patients were included. Median age at sampling was 36.2 years [IQR 27.0-49] with no statistical differences between groups. Most common syndromes at sampling in both seronegative-NMOSD and AQP4+NMOSD were myelitis (37% vs 54.2%) and optic neuritis (33.3% vs 37.5%). Median EDSS at sampling was 3.5 [IQR 2.5-7.0], with no significant difference between the two groups. Serum GFAP, Tau and UCH-L1 levels were significantly higher in AQP4+NMOSD compared to seronegative-NMOSD patients (median 304.1 vs 160.5 pg/mL p=0.005; median 24.8 vs 13.3 pg/mL, p= 0.002; and median 60 vs 37.3 pg/mL, p=0.021, respectively), as confirmed by ROC analysis, while NfL levels were similar (p=0.270). In the seronegative-NMOSD group, NfL and UCH-L1 levels correlated with EDSS at attack nadir (rho 0.438, p=0.032 and rho 0.429 p=0.036, respectively), while in the AQP4+NMOSD group this correlation was observed for NfL, UCH-L1, and GFAP levels (rho 0.745, p=0.010; rho 0.448, p=0.32, rho 525, p= 0.010, respectively).

Conclusions serum GFAP, Tau, and UCH-L1 levels discriminate between AQP4+NMOSD and seronegative-NMOSD. The different biomarkers profile suggests heterogeneity of diseases and provides useful data to improve our understanding of these diseases

Authors/Disclosures
Sara Carta, MD (Neurology Unit, University of Verona) PRESENTER	An immediate family member of Dr. Carta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB .
Alessandro Dinoto, MD	The institution of Dr. Dinoto has received research support from Encephalitis International . The institution of Dr. Dinoto has received research support from Autoimmune Encephalitis Alliance.
Marco Alfonso Narduc Capobianco	Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Marco Alfonso Narduc Capobianco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Pierre Branger	Pierre Branger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NOVARTIS. Pierre Branger has received personal compensation in the range of $0-$499 for serving as a Consultant for BIOGEN. Pierre Branger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Pierre Branger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS.
Bertrand Audoin	No disclosure on file
Jennifer Aboab	Jennifer Aboab, 8220 has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI.
Caroline Papeix (GH Pitie Salpetriere)	Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN . Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE . Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Caroline Papeix has received personal compensation in the range of $0-$499 for serving as a Consultant for NOVARTIS .
Nicolas Collongues, MD (Hopital Civil)	Nicolas Collongues, MD has nothing to disclose.
	No disclosure on file
Helene Zephir (Hospital Roger Salengro)	Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for BIogen Idec. Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for BMS. Helene Zephir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion.
Alain Creange (Hopital Henri Mondor)	No disclosure on file
Bertrand Bourre	Bertrand Bourre has nothing to disclose.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic)	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Vyanka Redenbaugh, MB BCh BAO (Mayo Clinic)	Dr. Redenbaugh has nothing to disclose.
	No disclosure on file
Georgina Arrambide, MD, PhD (Cemcat, Vall d´Hebron University Hospital)	The institution of Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. The institution of Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage. The institution of Dr. Arrambide has received research support from Instituto de Salud Carlos III. Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving as a Travel support for scientific meetings with Novartis. Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving as a Travel support for scientific meetings with Roche. Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving as a Travel support for scientific meetings with ECTRIMS. Dr. Arrambide has received personal compensation in the range of $500-$4,999 for serving as a Travel support for scientific meetings with EAN. Dr. Arrambide has a non-compensated relationship as a Member of the Executive Committee with iWiMS that is relevant to AAN interests or activities. Dr. Arrambide has a non-compensated relationship as a Member of the steering committee with BioMS-eu that is relevant to AAN interests or activities. Dr. Arrambide has a non-compensated relationship as a Member of the steering group with MOGAD Eugene Devic European Network (MEDEN) that is relevant to AAN interests or activities. Dr. Arrambide has a non-compensated relationship as a Member of the editorial and scientific committee with Acta Neurológica Colombiana that is relevant to AAN interests or activities.
Alvaro Cobo Calvo	No disclosure on file
	No disclosure on file
Romain Marignier, MD, PhD (Lyon University Hospital)	Dr. Marignier has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ALEXION. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE.
Sara Mariotto, MD, PhD (Neurology Unit, University of Verona)	Dr. Mariotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen, Sanofi, Alexion, Roche, TSF, Dynamics, UCB, Novartis, Amgen, AAN. The institution of Dr. Mariotto has received research support from Ministero della Salute Italiano. The institution of Dr. Mariotto has received research support from TSF. The institution of Dr. Mariotto has received research support from GJF. The institution of Dr. Mariotto has received research support from Lundbeck.

��ɫ��

��ɫ��